Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T17:18:10.832Z.
Calculation as of: 2026-10-06T17:18:10.832Z.
Quote observation: 2026-10-06T17:15:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2f5c47113f9c506e2e082fd2a1fe30760bd520268ada69101bb9e18573fa4dd9
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$860.72M
EBITDA Yield
10.68%
TTM Avg
17.19%
3Y Avg
13.36%
5Y Avg
13.36%
Market Cap
$865.23M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$857.36M
EBITDA Yield
N/A
TTM Avg
5.29%
3Y Avg
9.22%
5Y Avg
17.53%
Market Cap
$881.22M
EBITDA Yield
17.01%
TTM Avg
17.01%
3Y Avg
17.01%
5Y Avg
17.01%
Market Cap
$842.52M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$835.55M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SI-BONE, Inc. (SIBN) | $862.50M | N/A | N/A | N/A | N/A |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $860.72M | 10.68% | 17.19% | 13.36% | 13.36% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $865.23M | N/A | N/A | N/A | N/A |
| SL Science Holding Ltd (SLBT)vs › | $857.63M | N/A | N/A | N/A | N/A |
| QuidelOrtho Corporation (QDEL)vs › | $857.36M | N/A | 5.29% | 9.22% | 17.53% |
| Arbutus Biopharma Corp (ABUS)vs › | $881.22M | 17.01% | 17.01% | 17.01% | 17.01% |
| SpyGlass Pharma, Inc. Common Stock (SGP)vs › | $842.52M | N/A | N/A | N/A | N/A |
| Pacific Biosciences of California, Inc. (PACB)vs › | $835.55M | N/A | N/A | N/A | N/A |
| Alumis Inc. (ALMS)vs › | $834.31M | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $830.54M | N/A | 3.15% | 3.15% | 3.15% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
